News
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups.